FDG-PET/CT-Scans and Biomarker Levels Predicting Clinical Outcome in Patients with Alveolar Echinococcosis-A Single-Center Cohort Study with 179 Patients

Overview

Journal Pathogens

Date 2023 Aug 25

PMID 37624001

Authors

Lynn Peters

Wanjie Jiang

Nina Eberhardt

Jurgen Benjamin Hagemann

Beate Gruner

Dennis Tappe

Affiliations

Soon will be listed here.

Abstract

Alveolar echinococcosis (AE) is a severe larval tapeworm infection with a variable clinical course of the disease. Reliable imaging techniques and biomarkers are needed to predict the course of the disease. 179 AE patients that received PET/CT scans between 2008 and 2012 were retrospectively included. From stored blood samples taken on the day of the scan, levels of IgE, parasite-specific serology, amyloid A, C-reactive protein, soluble interleukin 2 receptor, cytokeratin fragments, eosinophilic cell count, and eosinophil cationic protein were measured. Additionally, the current clinical outcome (cured, stable, or progressive disease) after a median duration of 8 years after baseline examination was assessed. Ultimately, an ordinal logistic regression was conducted to evaluate which imaging parameters and biomarkers independently influence the clinical outcome. In general, patients in need of medical treatment or with progressive disease, advanced PNM stages, and positive PET/CT scans exhibited higher levels of the respective biomarkers. However, only the parasite-specific serological markers and total IgE levels differed significantly between clinical groups, WHO PNM stages, and the results of the PET/CT scan. In the multivariate analysis, PET/CT results were a strong predictor of the clinical outcome (OR 8.908, 95%CI 3.019-26.285; < 0.001), and age at baseline was a moderate predictor (OR 1.031, 95%CI 1.003-1.060; = 0.029). The PET/CT scan is, preferably in combination with parasite-specific serology and IgE levels, a valuable tool in the clinical management of AE and is able to predict the course of the disease.

Citing Articles

Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.

Liu H, Xie Y, An X, Xu D, Cai S, Chu C Diagnostics (Basel). 2025; 15(5).

PMID: 40075832 PMC: 11898896. DOI: 10.3390/diagnostics15050585.

The expression of CTLA-4 in hepatic alveolar echinococcosis patients and blocking CTLA-4 to reverse T cell exhaustion in -infected mice.

Yang Y, Wuren T, Wu B, Cheng S, Fan H Front Immunol. 2024; 15:1358361.

PMID: 38605966 PMC: 11007148. DOI: 10.3389/fimmu.2024.1358361.

References

Torgerson P, Schweiger A, Deplazes P, Pohar M, Reichen J, Ammann R . Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol. 2008; 49(1):72-7. DOI: 10.1016/j.jhep.2008.03.023. View

Peters L, Burkert S, Hagemann J, Albes R, Klemptner J, Birkle J . Initial Risk Assessment in Patients with Alveolar Echinococcosis-Results from a Retrospective Cohort Study. Pathogens. 2022; 11(5). PMC: 9144025. DOI: 10.3390/pathogens11050557. View

Gruner B, Kern P, Mayer B, Grater T, Hillenbrand A, Barth T . Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany. GMS Infect Dis. 2019; 5:Doc01. PMC: 6301735. DOI: 10.3205/id000027. View

Ammann R, Stumpe K, Grimm F, Deplazes P, Huber S, Bertogg K . Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-EmII/3-10 Serology. PLoS Negl Trop Dis. 2015; 9(9):e0003964. PMC: 4577091. DOI: 10.1371/journal.pntd.0003964. View

Husmann L, Gruenig H, Reiner C, Deibel A, Ledergerber B, Liberini V . Prediction of benzimidazole therapy duration with PET/CT in inoperable patients with alveolar echinococcosis. Sci Rep. 2022; 12(1):11392. PMC: 9259695. DOI: 10.1038/s41598-022-15641-5. View

Kern P, Wen H, Sato N, Vuitton D, Gruener B, Shao Y . WHO classification of alveolar echinococcosis: principles and application. Parasitol Int. 2005; 55 Suppl:S283-7. DOI: 10.1016/j.parint.2005.11.041. View

Fujimoto Y, Ito A, Ishikawa Y, Inoue M, Suzuki Y, Ohhira M . Usefulness of recombinant Em18-ELISA to evaluate efficacy of treatment in patients with alveolar echinococcosis. J Gastroenterol. 2005; 40(4):426-31. DOI: 10.1007/s00535-004-1559-7. View

Tappe D, Frosch M, Sako Y, Itoh S, Gruner B, Reuter S . Close relationship between clinical regression and specific serology in the follow-up of patients with alveolar echinococcosis in different clinical stages. Am J Trop Med Hyg. 2009; 80(5):792-7. View

Newgard C, Haukoos J . Advanced statistics: missing data in clinical research--part 2: multiple imputation. Acad Emerg Med. 2007; 14(7):669-78. DOI: 10.1197/j.aem.2006.11.038. View

10.

Piarroux M, Piarroux R, Giorgi R, Knapp J, Bardonnet K, Sudre B . Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients. J Hepatol. 2011; 55(5):1025-33. DOI: 10.1016/j.jhep.2011.02.018. View

11.

Deplazes P, Rinaldi L, Alvarez Rojas C, Torgerson P, Harandi M, Romig T . Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol. 2017; 95:315-493. DOI: 10.1016/bs.apar.2016.11.001. View

12.

Hotz J, Peters L, Kapp-Schworer S, Theis F, Eberhardt N, Essig A . Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and -Specific IgG. Pathogens. 2022; 11(2). PMC: 8880252. DOI: 10.3390/pathogens11020239. View

13.

Tabuchi M, Tomioka K, Kawakami T, Murakami Y, Hiramatsu M, Itoshima T . Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol (Tokyo). 2011; 56(5):271-8. DOI: 10.3177/jnsv.56.271. View

14.

Tappe D, Sako Y, Itoh S, Frosch M, Gruner B, Kern P . Immunoglobulin G subclass responses to recombinant Em18 in the follow-up of patients with alveolar echinococcosis in different clinical stages. Clin Vaccine Immunol. 2010; 17(6):944-8. PMC: 2884418. DOI: 10.1128/CVI.00026-10. View

15.

Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U . Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood. 2007; 110(13):4535-42. DOI: 10.1182/blood-2006-10-049817. View

16.

Gruner B, Peters L, Hillenbrand A, Vossberg P, Schweiker J, Rollmann E . Echinococcus multilocularis specific antibody, systemic cytokine, and chemokine levels, as well as antigen-specific cellular responses in patients with progressive, stable, and cured alveolar echinococcosis: A 10-year follow-up. PLoS Negl Trop Dis. 2022; 16(2):e0010099. PMC: 8809567. DOI: 10.1371/journal.pntd.0010099. View

17.

Brunetti E, Kern P, Vuitton D . Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2009; 114(1):1-16. DOI: 10.1016/j.actatropica.2009.11.001. View

18.

Deibel A, Stocker D, Meyer Zu Schwabedissen C, Husmann L, Kronenberg P, Grimm F . Evaluation of a structured treatment discontinuation in patients with inoperable alveolar echinococcosis on long-term benzimidazole therapy: A retrospective cohort study. PLoS Negl Trop Dis. 2022; 16(1):e0010146. PMC: 8827419. DOI: 10.1371/journal.pntd.0010146. View

19.

Husmann L, Deibel A, Skawran S, Ledergerber B, Muehlematter U, Hasse B . Follow-up PET/CT of alveolar echinococcosis: Comparison of metabolic activity and immunodiagnostic testing. PLoS One. 2022; 17(6):e0270695. PMC: 9242476. DOI: 10.1371/journal.pone.0270695. View

20.

Kern P . Clinical features and treatment of alveolar echinococcosis. Curr Opin Infect Dis. 2010; 23(5):505-12. DOI: 10.1097/QCO.0b013e32833d7516. View